Zobrazeno 1 - 10
of 558
pro vyhledávání: '"M Lichtenauer"'
Autor:
J. H. Niebauer, A. Iscel, S. Schedl, C. Capelle, M. Kahr, S. Schamilow, J. Faltas, M. Srdits, R. Badr-Eslam, M. Lichtenauer, A. Zoufaly, R. Valenta, S. Hoffmann, S. Charwat-Resl, C. Krestan, W. Hitzl, C. Wenisch, D. Bonderman
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionSARS-CoV-2 infection affects the cardiopulmonary system in the acute as well as long-term phase. The aim of the present study was to comprehensively assess symptoms and possible long-term impairments 6 and 18 months after hospitalization
Externí odkaz:
https://doaj.org/article/9befd1262cf541f28be85357de83c21e
Autor:
Michael Boehm, Rebecca Herzog, Florian Klinglmüller, Anton M. Lichtenauer, Anja Wagner, Markus Unterwurzacher, Robert H. J. Beelen, Seth L. Alper, Christoph Aufricht, Klaus Kratochwill
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Peritoneal dialysis (PD) fluids are cytotoxic to the peritoneum. Recent studies have shown that alanyl-glutamine (AlaGln) modulates the cellular stress response, improves mesothelial cell survival, reduces submesothelial thickening in experimental mo
Externí odkaz:
https://doaj.org/article/f1d89c7e5dab4eaaa466f7e47949166f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rebecca Herzog, Maria Bartosova, Silvia Tarantino, Anja Wagner, Markus Unterwurzacher, Juan Manuel Sacnun, Anton M. Lichtenauer, Lilian Kuster, Betti Schaefer, Seth L. Alper, Christoph Aufricht, Claus Peter Schmitt, Klaus Kratochwill
Publikováno v:
Biomolecules, Vol 10, Iss 12, p 1678 (2020)
Long-term clinical outcome of peritoneal dialysis (PD) depends on adequate removal of small solutes and water. The peritoneal endothelium represents the key barrier and peritoneal transport dysfunction is associated with vascular changes. Alanyl-glut
Externí odkaz:
https://doaj.org/article/8f17bc687ed9425b8b701a9d87f3e2bd
Autor:
P Jirak, V Van Almsick, D Dimitroulis, M Mirna, C Seelmaier, Z Shomanova, D Semo, D Dankl, M Mahringer, M Lichtenauer, U Hoppe, H Reinecke, R Pistulli, R Larbig, L Motloch
Publikováno v:
European Heart Journal. 43
Background Severe COVID-19 pneumonia requiring intensive care treatment remains a clinical challenge to date. Dexamethasone was reported as a promising treatment option, leading to a reduction of mortality rates in severe COVID-19 disease. However, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0514d60fc54afa2d20da7c0ae80a604
https://doi.org/10.1093/eurheartj/ehac544.1478
https://doi.org/10.1093/eurheartj/ehac544.1478
Autor:
V Van Almsick, P Jirak, D Dimitroulis, M Mirna, C Seelmaier, Z Shomanova, D Semo, D Dankl, M Mahringer, M Lichtenauer, U Hoppe, H Reinecke, R Larbig, L Motloch, R Pistulli
Publikováno v:
European Heart Journal. 43
Aims/Background Severe COVID-19 pneumonia requiring intensive care treatment remains a clinical challenge to date. Dexamethasone was reported as a promising treatment option, leading to a reduction of mortality rates in severe COVID-19 disease as wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccb9b65e1714fafce3feb5c0c4cd67af
https://doi.org/10.1093/eurheartj/ehac544.1271
https://doi.org/10.1093/eurheartj/ehac544.1271
Autor:
J Niebauer, C Binder, A Iscel, S Klenk, C Capelle, M Kahr, S Cadjo, M Lichtenauer, A Toma, A Zoufaly, S Hoffman, S Charwat-Resl, C Krestan, C Wenisch, D Bonderman
Publikováno v:
European Heart Journal. 43
Background Multiple studies have described acute effects of the Covid-19 infection on the heart, but little is known about the long-term cardiac and pulmonary effects and complications after recovery. The aim of this analysis was to deliver a compreh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca36e1adb90a608dea125b4286dceb82
https://doi.org/10.1093/eurheartj/ehac544.249
https://doi.org/10.1093/eurheartj/ehac544.249
Autor:
T Froehling, M Mirna, V Paar, Z Shomanova, V Van Almsick, L J Motloch, D Semo, L Makowski, A Rukosujew, J R Sindermann, H Reinecke, M Lichtenauer, R Pistulli
Publikováno v:
European Heart Journal. 43
Aims Heart failure (HF) remains a major therapeutic and diagnostic challenge. In this study we aimed to analyze the predictive potential of four novel cardiovascular biomarkers – soluble urokinase-type plasminogen activator receptor (suPAR), vascul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c68250125910d5377e92a00f8ea4f023
https://doi.org/10.1093/eurheartj/ehac544.911
https://doi.org/10.1093/eurheartj/ehac544.911
Autor:
B Ohnewein, Z Shomanova, P Jirak, A Topf, E J Froeb, C Pogoda, C Granitz, M Lichtenauer, U Hoppe, H Reinecke, R Pistulli, L J Motloch
Publikováno v:
European Heart Journal. 43
Background Heart Failure with reduced ejection fraction (HFrEF) has a life time risk about 20% among adults aged 40 years or older and a 5-year mortality rate about 60% [1,2]. However novel therapies have shown to improve this outcome. One novel agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e151bd8cab03cc22360b40a899d722a
https://doi.org/10.1093/eurheartj/ehac544.974
https://doi.org/10.1093/eurheartj/ehac544.974
Autor:
E Boxhammer, M Bellamine, I Szendey, J Kletzer, M Foresti, J Kraus, F Danmayr, A Topf, P Jirak, M Bonsels, M Lichtenauer, U C Hoppe, B Strohmer, L J Motloch, R Larbig
Publikováno v:
European Heart Journal. 43
Background The CASTLE-AF trial in 2018, showed that pulmonary vein isolation provides a survival benefit and a reduced hospitalization rate in patients with heart failure and concomitant atrial fibrillation. Typical atrial flutter (AFL) can also indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9df3ec2dc146c749d010a0a0f058692e
https://doi.org/10.1093/eurheartj/ehac544.460
https://doi.org/10.1093/eurheartj/ehac544.460